Toxicology International (Formerly Indian Journal of Toxicology)

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Safety Assessment of Marbofloxacin Following Repeated Intramuscular Administration in Goats


Affiliations
1 Dept. of Vety. Pharmacology and Toxicology, GADVASU, Ludhiana, Punjab, India
2 Dept. of Vety. Physiology and Biochemistry, COVAS, CSKHPKV, Palampur, H.P, India
     

   Subscribe/Renew Journal


Marbofloxacin (MB) is an extended spectrum, third generation fluoroquinolone, developed exclusively for the use in veterinary medicine. The safety assessment was done to evaluate the clinical impact of marbofloxacin after repeated intramuscular administration in goats. Safety of drugs is important and changes in serum biochemical and/or hematological markers could provide an early indication of cellular toxicity. The drug was administered at the dose of 2 mg/kg for 5 days by intramuscular route in six healthy, non-lactating Beetal goats, 1.5-2 yrs of age. Haematological (TLC, TEC, Hb, PCV, MCV, MCH and MCHC) and serum biochemical parameters viz. liver function test (LFT) and kidney function test (KFT) (ALT, AST, ALP, GGT, BUN, creatinine, total proteins and albumin) were determined and analyzed to establish the safety profile of marbofloxacin. The hematological and biochemical parameters were found to fluctuate within normal range during treatment period and no significant alterations (p < 0.05) were found in the mean values. The results indicated that intramuscular administration of marbofloxacin in goats at the dose of 2 mg/kg for 5 days seems to be safe.

Keywords

Marbofloxacin, Repeated Administration, Safety Assessment, Goats.
User
Subscription Login to verify subscription
Notifications
Font Size

  • Schneider M, Thomas V, Boisrame B, Deleforge J. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. Journal of Veterinary Pharmacology and Therapeutics 1996;19:56-61.

  • Spreng M, Deleforge J, Thomas V, Boisrame B, Drugeon H. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. Journal of Veterinary Pharmacology and Therapeutics 1995;18:284-89.

  • Brown SA. Fluoroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics 1996;19:1-14.

  • Thomas A, Nicolas C, Dizier I, Mainil J, Linden A. Antibiotic susceptibilities of recent isolates of Mycoplasma bovis in Belgium. Veterinary Record 2003;153:428-31.

  • Aliabadi FS and Lees P. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics 2002;25:161-74.

  • Thomas E, Madelenat A, Davot JL, Boisrame B. Clinical efficacy and tolerance of marbofloxacin and tetracycline in the treatment of bovine respiratory disease. Revue MedecineVeterinaire1998; 174:21-27.

  • Thomas E, Caldow GL, Borell D, Davot JL. A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of bovine respiratory disease. Journal of Veterinary Pharmacology and Therapeutics 2001;24:353-58.

  • Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, Safety, and Tolerability of, Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects. Antimicrobial agents and Chemotherapy 1998;42(8):2060-65.

  • Bhavsar SK, Verma MP, Thaker AM. Pharmacokinetics, tissue concentration and safety of multiple dose Intravenous administration of ciprofloxacin in cow calves. J. Vet. Pharmacol. Toxicol.2004;3(1):27-34.

  • Khargharia S, Barua CC, Nath N, Bhattachrya M. Blood Biochemical Studies of Enrofloxacin in Yak after Intravenous Administration. Iranian J.Pharmacol.Therap. 2007;6:137-38.

  • Patel JH, Varia RD, Patel UD, Vihol PD, Bhavsar SK and Thaker AM. Safety level of levofloxacin following repeated oral administration in White Leg Horn layer birds. Veterinary world2009;2(4):137-39.

  • Sadariya KA, Gothi AK, Patel SD, Bhavsar SK and Thaker AM. Safety of Moxifloxacin following repeated intramuscular administration in Wistar rat. Veterinary World 2010;3(10):449-52

  • Kim JC, Shin DH, Ahn TH, Kang SS, Song SW, Han J, Kim CY, Ha CS, Chung MK. 26-week repeated oral dose toxicity study of the new quinolone antibacterial DW 116 in prague–Dawley rats. Food and Chem. Toxicol.2003;41(5):637-45.

  • Keutz EV and Schluter G. Preclinical safety evalution of Moxifloxacin, a novel fluoroquinolones. Journal of antimicrobial Chemotherapy1999;43:91-100.

  • Lu GC, She JH, Jiang H, Li ZY, Yuan BJ. Sixty-day repeated dose toxicity of sinafloxacin in rats and dogs. Food and chemical toxicology2008;46(2):575-80.

  • Zhao B, Chingnell CF, Rammal M, Smith F, Hamilton MG, Roberts JE. Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics. Phototoxicity and Photobiology 2010;86(4):798-805

  • Wiebe V and Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. Journal of the American Veterinary Medical Association 2002;221:1568-71

  • Ford MM, Dubielzig RR, Giuliano EA, Moore CP and Narfstrom KL. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. American Journal of Veterinary research 2007;68(2):190-202

  • Rampal S, Kaur R, Sethi R, Singh O, Sood N. Ofloxacin-associated retinopathy in rabbits: role of oxidative stress. Human and Experimental Toxicology 2008;27:409-15

  • FrydmanAM, Roux YL, Lefebrre MA, Djebbai F, Foartfflan JB,Gafflof J. Pharmacokinetics of pefloxacin after repeated intravenons and oral administration (400 mg bid) in young healthy volunteers. Journal of Antimicrobial Chemotherapy 1986;17(B):65-79.

  • Schneider M, Valle M, Woehrle F, Boisrame B. Pharmacokinetics of marbofloxacin in lactating cows after repeated intramuscular administrations and pharmacodynamics against mastitis isolated strains. Journal of Dairy Science 2004;87:202-11

  • Shimoda K, Okawara S, Kato M. Phototoxic retinal degeneration and toxicokinetics of sitafloxacin, a quinolone antibacterial agent, in mice. Archives of Toxicology 2001;75: 395-99

  • Nix D E and Schentag JJ. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. Journal of Clinical Pharmacology 1988;28:169-78.

  • Chang T, Black A, Dunkey A, Wolf R, Sedman A, Latts J, Welling PG. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 1988;21(B):49-56.

  • Sarkozy G. Quinolones: a class of antimicrobial agents. Veterinary Medicine-Czech 2001;46(9-10):257-74.e


Abstract Views: 271

PDF Views: 0




  • Safety Assessment of Marbofloxacin Following Repeated Intramuscular Administration in Goats

Abstract Views: 271  |  PDF Views: 0

Authors

Pallavi Bhardwaj
Dept. of Vety. Pharmacology and Toxicology, GADVASU, Ludhiana, Punjab, India
G. Singh
Dept. of Vety. Physiology and Biochemistry, COVAS, CSKHPKV, Palampur, H.P, India
Saloni Singla
Dept. of Vety. Pharmacology and Toxicology, GADVASU, Ludhiana, Punjab, India
S. K. Sharma
Dept. of Vety. Pharmacology and Toxicology, GADVASU, Ludhiana, Punjab, India
S. Rampal
Dept. of Vety. Pharmacology and Toxicology, GADVASU, Ludhiana, Punjab, India

Abstract


Marbofloxacin (MB) is an extended spectrum, third generation fluoroquinolone, developed exclusively for the use in veterinary medicine. The safety assessment was done to evaluate the clinical impact of marbofloxacin after repeated intramuscular administration in goats. Safety of drugs is important and changes in serum biochemical and/or hematological markers could provide an early indication of cellular toxicity. The drug was administered at the dose of 2 mg/kg for 5 days by intramuscular route in six healthy, non-lactating Beetal goats, 1.5-2 yrs of age. Haematological (TLC, TEC, Hb, PCV, MCV, MCH and MCHC) and serum biochemical parameters viz. liver function test (LFT) and kidney function test (KFT) (ALT, AST, ALP, GGT, BUN, creatinine, total proteins and albumin) were determined and analyzed to establish the safety profile of marbofloxacin. The hematological and biochemical parameters were found to fluctuate within normal range during treatment period and no significant alterations (p < 0.05) were found in the mean values. The results indicated that intramuscular administration of marbofloxacin in goats at the dose of 2 mg/kg for 5 days seems to be safe.

Keywords


Marbofloxacin, Repeated Administration, Safety Assessment, Goats.

References





DOI: https://doi.org/10.22506/ti%2F2017%2Fv24%2Fi3%2F166509